GlassScriptPhysician profile
Anna M Cook
NPI 1063721314
$53,814.43
in general payments reported to CMS, 2019-2025
20 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $902 · 2023: $775 · 2024: $26K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Honoraria: $22K · Food and Beverage: $4,119 · Travel and Lodging: $3,129 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,426.00 |
| Honoraria | $22,425.00 |
| Food and Beverage | $4,118.81 |
| Travel and Lodging | $3,129.03 |
| Education | $299.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $49,986.69 | 2023-2025 | Auvelity |
| Corium, LLC | $792.56 | 2022-2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $715.67 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $675.42 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $249.42 | 2021-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $233.37 | 2021-2025 | Rexulti |
| Alkermes, INC. | $221.19 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.01 | 2021-2025 | Caplyta |
| Lundbeck LLC | $154.90 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $116.73 | 2021-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $104.76 | 2021-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $82.16 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $76.87 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $47.76 | 2024-2025 | Trintellix |
| Tris Pharma INC | $44.12 | 2025 | Dyanavel Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $33.69 | 2021 | |
| Acadia Pharmaceuticals INC | $29.04 | 2024 | Nuplazid |
| Tempus Ai, INC | $24.30 | 2024 | |
| Novo Nordisk INC | $24.05 | 2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $18.72 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.